Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Expert Rev Vaccines ; 22(1): 1136-1153, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37936254

RESUMO

INTRODUCTION: Fungal infections are caused by a broad range of pathogenic fungi that are found worldwide with different geographic distributions, incidences, and mortality rates. Considering that there are relatively few approved medications available for combating fungal diseases and no vaccine formulation commercially available, multiple groups are searching for new antifungal drugs, examining drugs for repurposing and developing antifungal vaccines, in order to control deaths, sequels, and the spread of these complex infections. AREAS COVERED: This review provides a summary of advances in fungal vaccine studies and the different approaches under development, such as subunit vaccines, whole organism vaccines, and DNA vaccines, as well as studies that optimize the use of adjuvants. We conducted a literature search of the PubMed with terms: fungal vaccines and genus of fungal pathogens (Cryptococcus spp. Candida spp. Coccidioides spp. Aspergillus spp. Sporothrix spp. Histoplasma spp. Paracoccidioides spp. Pneumocystis spp. and the Mucorales order), a total of 177 articles were collected from database. EXPERT OPINION: Problems regarding the immune response development in an immunocompromised organism, the similarity between fungal and mammalian cells, and the lack of attention by health organizations to fungal infections are closely related to the fact that, at present, there are no fungal vaccines available for clinical use.


Assuntos
Micoses , Vacinas , Animais , Humanos , Antifúngicos/uso terapêutico , Fungos , Micoses/prevenção & controle , Micoses/tratamento farmacológico , Micoses/epidemiologia , Vacinas/uso terapêutico , Desenvolvimento de Vacinas , Mamíferos
2.
Mol Cell Endocrinol ; 506: 110754, 2020 04 15.
Artigo em Inglês | MEDLINE | ID: mdl-32044375

RESUMO

EPPIN is a sperm-surface drug target for male contraception. Here we investigated EPPIN-interacting proteins in mouse spermatozoa. We showed that EPPIN is an androgen-dependent gene, expressed in the testis and epididymis, but also present in the vas deferens, seminal vesicle and adrenal gland. Mature spermatozoa presented EPPIN staining on the head and flagellum. Immunoprecipitation of EPPIN from spermatozoa pre-incubated with seminal vesicle fluid (SVF) followed by LC-MS/MS or Western blot revealed the co-immunoprecipitation of SVS2, SVS3A, SVS5 and SVS6. In silico and Far-Western blot approaches demonstrated that EPPIN binds SVS2 in a protein network with other SVS proteins. Immunofluorescence using spermatozoa pre-incubated with SVF or recombinant SVS2 demonstrated the co-localization of EPPIN and SVS2 both on sperm head and flagellum. Our data show that EPPIN's roles in sperm function are conserved between mouse and human, demonstrating that the mouse is a suitable experimental model for translational studies on EPPIN.


Assuntos
Proteínas Secretadas Inibidoras de Proteinases/fisiologia , Proteínas Secretadas pela Vesícula Seminal/metabolismo , Espermatozoides/metabolismo , Androgênios/metabolismo , Animais , Cromatografia Líquida , Epididimo/química , Epididimo/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Ligação Proteica , Mapas de Interação de Proteínas/genética , Proteínas Secretadas Inibidoras de Proteinases/metabolismo , Espermatozoides/química , Espectrometria de Massas em Tandem , Testículo/química , Testículo/metabolismo
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa